J&J Eyes Cost-Effectiveness In R&D; Scientists Trained In Health Economics
Executive Summary
Johnson & Johnson is training its drug discovery scientists in pharmacoeconomics as one way to help contain future drug costs, Pharmaceutical R&D Chairman Per Peterson said during the company's R&D day in New York May 26
You may also be interested in...
PhRMA Must Tackle Cost-Effectiveness “Dilemma,” J&J’s Weldon Says
The Pharmaceutical Research & Manufacturers of America is considering the development of principles on evidence-based medicine to help it engage more directly in the debate over the cost-effectiveness of medicines
CMS Suggests “Pay For Performance” Approach To Cancer Drug Coverage
The ideal approach to cancer drug reimbursement would tie payment to patient outcomes, Centers for Medicare & Medicaid Services Administrator Mark McClellan said June 15 at a Manhattan Institute luncheon in New York
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011